Cartridges comprising tablets

By immobilizing tablets between flexible foils in PCR chambers, the stability and reliability of PCR performance are enhanced, addressing the challenges of ingredient stability and clogging in microfluidic cartridges, and simplifying the manufacturing process.

WO2024240872A1PCT designated stage expired Publication Date: 2024-11-28BIOCARTIS NV
View PDF 14 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2024/064208
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-23
Filing Date
2024-05-23
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Microfluidic PCR cartridges face challenges in maintaining stability of PCR ingredients under varying conditions, requiring costly and error-prone heat-drying processes, and preloaded dosage forms can clog outlet channels and disrupt meniscus movement, leading to unreliable PCR performance.

Method used

The dosage forms, such as tablets, are immobilized in PCR chambers by clamping or sandwiching between flexible, transparent foils on top and bottom layers, allowing for even dissolution and preventing air trapping, without the need for specialized equipment or adjustments to manufacturing machinery.

Benefits of technology

This method ensures reliable and consistent PCR performance, reduces manufacturing costs, minimizes handling errors, and maintains stability of PCR components, while avoiding clogging and air entrapment issues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2024064208_28112024_PF_FP_ABST
    Figure EP2024064208_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to microfluidic devices comprising preloaded dosage forms that are relatively simple and inexpensive to manufacture, without the need for specialized equipment. The dosage forms are deposited and immobilized in the PCR chambers by clamping or sandwiching the dosage form between the transparent foils located on the top and / or bottom of the PCR chamber, resulting in a reliable and consistent performance of the PCR process. The advantages of this method are manifold: there is no air trapping, no occlusion of outlet ports, no costly adjustments to the manufacturing machinery are necessary, the dosage form is dissolved evenly, and there is a robust readout.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CARTRIDGES COMPRISING TABLETS

[0002] TECHNICAL FIELD

[0003] The present invention relates to microfluidic devices comprising preloaded dosage forms that are relatively simple and inexpensive to manufacture, without the need for specialized equipment. The dosage forms are deposited and immobilized in the Polymerase Chain Reaction ("PCR") chambers by clamping or sandwiching the dosage form between the transparent foils located on the top and / or bottom of the PCR chamber, resulting in a reliable and consistent performance of the PCR process. The advantages of this method are manifold: there is no air trapping, no occlusion of outlet ports, no costly adjustments to the manufacturing machinery are necessary, the dosage form is dissolved evenly, and there is a robust readout.

[0004] BACKGROUND

[0005] Microfluidic (lab-on-the-chip or LOC) PCR array cartridges are very versatile and are used in a growing number of diagnostic assays. The cartridges support sample preparation, nucleic acid amplification, multiplexing and detection. These microfluidic cartridges are part of a user-friendly, autonomic operational platform, such as the Idylla™ platform by Biocartis NV. The microfluidic cartridges allow DNA / RNA extraction, followed by purification, amplification of nucleic acids and automatic detection. The user only has to collect the sample, inject the raw sample into the cartridge, insert the cartridge into the instrument, which automatically supports microfluidics within the cartridge, and then press the "start" button. This automated and contained process flow protects the sample from contamination and minimizes the user's exposure to the sample. The microfluidic cartridges can have a multi-chamber array, in which all of the PCR chambers receive the same sample, but each PCR chamber is dedicated to one or more particular targets, e.g. each chamber has its specific primers, probes and / or labels different from adjacent chambers, allowing detection of multiple targets in one test run. These real-time PCR easy-to- use cartridges for diagnostic purposes revolutionized diagnosis and as a result the treatment paradigm.

[0006] The cartridges are shipped all over the world under varying conditions and requiring extensive storage periods before use.

[0007] A problem is that PCR ingredients, including enzymes, must be stable under these varying conditions and over extended time frames. Since treatment depends on the results of the tests, the reliability and robustness of the test is an absolute requirement. A solution to maintain stability of the components was heat-drying the various PCR and detection ingredients, such primers, probes, enzymes, directly in the different PCR chambers.

[0008] However, due to the small size of the PCR chambers, the number of PCR chambers in the cartridges and the necessity to avoid contamination, this is a costly and error prone procedure, which necessitated specialized equipment and highly skilled personnel.

[0009] Some companies therefore decoupled the manufacturing of the cartridges and the deposition process of the PCR mixes for the different PCR chambers. The PCR components were freeze-dried and subsequently assembled and pressed into a tablet. These tablets can be stored individually, and when necessary dispensed into the system. These tablets allow the preparation of off-the-shelf, preoptimized, and premixed PCR reaction mixes. An example of this is the Cepheid GeneXpert® system using enzyme beads and target specific reagent beads. However, the Cepheid GeneXpert® system requires a specific design of the apparatus and PCR chambers, which reduces standardization and increases costs.

[0010] Hence, there is a need for a simplified, ubiquitously useful system, providing flexibility while retaining reliability.

[0011] SUMMARY OF THE INVENTION

[0012] The inventor realized that decoupling the manufacturing of the microfluidic device, e.g. a cartridge or LOC, and the heat-drying process of the PCR mixes for the different PCR chambers may reduce the manufacturing costs, handling error, minimize the time, manual work, and skilled labor. The inventor set out to provide a microfluidic device comprising preloaded dosage forms that are relatively simple and inexpensive to manufacture and without the need for specialized equipment. After assessment, the process flow on pre-existing manufacturing lines was redesigned and implemented, necessitating only a minimal, reversible adjustment, in that the dosage forms were deposited in the PCR chambers instead of heat-drying the components in the PCR chambers. In addition, a dosage form provides an extra flexibility in that the most suitable drying process can be used, e.g. some PCR mixes (enzymes) have a larger stability and longer shelf-life when freeze-dried into a dosage form (e.g. tablet) compared to heat-drying in the PCR chamber. Depositing the dosage forms in the various reaction chambers by the manufacturer also reduces the risks of mishandling the different dosage forms by the user in contemporaneous systems.

[0013] However, a problem that frequently was encountered with preloaded dosage forms is obstructing and clogging of the outlet channels when the sample enters the PCR chamber. Another problem resides in the movement of the meniscus of a sample as it loads the PCR chamber with a preloaded dosage form, which can result in entrapment of a gas bubble within the PCR chamber.

[0014] Physical modification of the PCR chamber to affix the dosage form, such as adjusting the interior shape of the chamber or introducing clamping features to control the location of the dosage form, should not block -even partially- the light rays and distort detection. Chemical modification to control the location of the PCR dosage form is not preferred either, since it would introduce extra components, that potentially influence the PCR process and / or detection.

[0015] The inventor recognized that the dosage form, such as a tablet, could be immobilized in the PCR chamber by clamping or sandwiching the dosage form between the flexible, transparent foil(s) located on the top and / or bottom of the PCR chamber. They surprisingly observed that immobilizing the dosage form in the PCR chamber resulted in a reliable and consistent performance of the PCR process. The advantages of this method are manifold: there is no air trapping, no occlusion of outlet ports, no costly adjustments to the manufacturing machinery are necessary, the dosage form is dissolved evenly, and there is a robust readout.

[0016] In accordance with various exemplary aspects, the invention relates to a microfluidic chamber, configured to be loaded with a sample fluid, such as a biological sample, comprising: a top layer comprising a first material; a bottom layer comprising a second material; wherein the top layer and the bottom layer oppose each other; wherein at least one of the first material and the second material is flexible; and wherein at least one of the first material and the second material is transparent; a wall having a first surface and a second surface, wherein the first surface of the wall is affixed to the top layer and the second surface of the wall is affixed to the bottom layer, and wherein the top layer, bottom layer, and wall form a cavity of the chamber; an inlet in the wall; an outlet in the wall, and a dosage form, preferably a tablet, that is immobilized in the cavity and that engages the top layer and the bottom layer, wherein engagement with the top layer and the bottom layer immobilizes the dosage form within the cavity.

[0017] According to various exemplary embodiments, a microfluidic device may include a sample distribution network including a plurality of microfluidic chambers configured to be loaded with sample fluid, such as a biological sample, for testing of the sample fluid while in the microfluidic chambers, the sample fluid having a meniscus that moves within the sample chambers during loading. The sample distribution network may also include a plurality of inlet channels, each inlet channel being in flow communication with and configured to flow sample fluid to a respective microfluidic chamber, and a plurality of outlet channels, each outlet channel being in flow communication with and configured to flow sample fluid from a respective microfluidic chamber. At least some of the microfluidic chambers may include a physical modification configured to control the movement of the meniscus so as to control bubble formation within the at least some microfluidic chambers. The channels may comprise valves for regulating the flow communication.

[0018] The invention is further defined by the appended claims. Additional features and advantages of the concepts disclosed herein are set forth in the description and figures which follows, and in part will be obvious from the description, or may be learned by practice of the described technologies. The features and advantages of the concepts may be realized and obtained by means of the instruments and combinations particularly pointed out in the appended claims. These and other features of the described technologies will become more fully apparent from the following description, figures and appended claims, or may be learned by the practice of the disclosed concepts as set forth herein.

[0019] BRIEF DESCRIPTION OF THE FIGURES

[0020] The figures of this application illustrate exemplary embodiments of the invention and together with the description, serve to explain certain principles:

[0021] Figure 1: shows in a sectional side view an empty PCR chamber (1), i.e. without a dosage form, located in the main body of a PCR disk (4). The PCR chamber (1) comprises a top layer comprising a first flexible, preferably transparent, material (7) and a bottom layer comprising a second flexible, preferably transparent, material (8), wherein the top layer and the bottom layer oppose each other. The walls (3) of the PCR chamber having a first surface (5) and a second surface (6), wherein the first surface (5) of the wall is affixed (mounted) to the top layer (7) and the second surface of the wall (6) is affixed (mounted) to the bottom layer (8), and wherein the top layer (7), bottom layer (8), and wall (3) form a cavity (2) of the chamber. The first and second flexible material are respectively affixed to the first surface (5) and a second surface (6) of the walls (3) of the PCR chamber (1) via welding (10), in which the welding circumference or perimeter Pw is localized outward from the cavity perimeter Pc, i.e. Pw > Pc. The indentations at (10) represent welding seams. Figure 2: is a cross-sectional view of an exemplary embodiment of a PCR chamber (1), located in the main body of a PCR disk (4), wherein the cavity (2) of the PCR chamber comprises a tablet (9), that is immobilized in the cavity (2) and that engages the top layer (7) and the bottom layer

[0022] (8), wherein the height (17) of the tablet (9) is slightly larger than the height (18) of the walls (3) of the PCR chamber (1), and wherein the first layer (7) and second layer (8) are respectively affixed to the first surface (5) and a second surface (6) of the walls (3) of the PCR chamber (1) via welding, of which the welding circumference (10) is localized outward from the perimeter of the cavity (2).

[0023] Figure 3: shows a photograph of a reaction element, a PCR disk (4), containing a main fluid channel (14), and 5 PCR chambers (1), which are aligned radially from the centrally located waste chamber (11), the top layer (7) comprising a first flexible, transparent material covering the PCR disk (indicated as top foil). Each PCR chamber with an inlet- (19) and outlet- (20) channel, in which the inlet channels are in fluid connection with the main fluid (or central) channel (14), and in which the outlet channels are in fluid connection with the waste chamber (11).

[0024] Figure 4: shows a photograph of the PCR disk of Figure 3, in which one PCR chamber comprises a tablet

[0025] (9), which is immobilized within the cavity of the PCR chamber by engaging with the top layer comprising the first flexible, transparent material and the bottom layer comprising the second flexible, transparent material.

[0026] Figure 5: is a schematic representation of a top sectional view of a PCR chamber (1), located in the main body of a PCR disk (4), wherein the cavity (2) of the chamber comprises a tablet (9), that is immobilized in the cavity (2) and that engages the top layer (7) and the bottom layer (8) (not shown), in which the PCR chamber (1) has an inlet channel (19) and an outlet channel (20). The outlet channel (20) is in fluid connection with the waste chamber (11) (not shown). The inlet channel (19) is configured to direct the sample fluid [S] to enter the PCR chamber (1) at the inlet (12) opening formed at the junction of the inlet channel (19) with the PCR chamber (1). The walls of the PCR chamber are indicated by (3). Arrows (without numbers) denote the direction of the sample fluid [S] flow. Figure 5A shows an exemplary embodiment of a top sectional view of a PCR chamber (1), in which the inlet (12) opening formed at the junction of the inlet channel (19) with the PCR chamber (1) has two projecting members ("protrusions") (15) pointing inwards into the cavity (2), and which facilitate controlling meniscus [M] formation while loading the liquid sample. In this case the outlet (13) opening is located opposite to the inlet (12) opening. Figure 5B shows another exemplary embodiment of a top sectional view of a PCR chamber (1), in which the inlet (12) opening formed at the junction of the inlet channel (19) with the PCR chamber (1) has one projecting member (15) pointing inwards into the cavity (2), which facilitate controlling meniscus [M] formation while loading the sample. In this case the outlet (13) opening is located at about 90°+ 10° from the inlet (12) opening on the side of the projecting member (15).

[0027] Figure 6: shows a series of top sectional views of a PCR chamber (1), located in the main body of a PCR disk (4), and comprising a dosage form (9), while being filled with a sample S and meniscus M. The PCR chamber (1) comprises a cavity (2), which comprises the dosage form (9), e.g. a tablet, that is immobilized in the cavity (2) and that engages the top layer (7) and the bottom layer (8) (not shown), in which the PCR chamber (1) has an inlet channel (19) and an outlet channel (20). The inlet (12) opening formed at the junction of the inlet channel (19) with the PCR chamber (1) has two projecting members (15) pointing inwards of the cavity (2). The outlet channel (20) is in fluid connection with the waste chamber (11) (not shown). The inlet channel (19) is configured to direct the sample fluid S to enter the PCR chambers (1) at the inlet (12) opening formed at the junction of the inlet channel (19) with the PCR chamber (1). The walls of the PCR chamber are indicated by (3). Arrows (without numbers) denote the direction of the sample fluid S flow. Figure 6A shows the inlet channel (19) being filled with sample S, forming a meniscus M. Figure 6B shows the further progression of the meniscus M and sample S as it begins to load the cavity (2) of the PCR chamber (1) and advances in a substantially uniform manner when approaching the dosage form (9), e.g. a tablet, after which the sample S advances at both sides of the tablet (9) with two menisci Ml and M2. Figure 6C shows the two menisci Ml and M2 progressing at about the same rate in the cavity (2), pushing the gas in front of them towards the outlet opening (13) leading to the outlet channel (20) and towards the waste chamber (11) (not shown). Figure 6D shows the cavity (2) of the PCR chamber (1) that is completely filled with tablet (9) and sample S, which approaches outlet (13) leading to outlet channel (20). Figure 6E shows an overfill of the PCR chamber (1), in which part of the sample S entered the outlet channel (20).

[0028] Figure 7: is a schematic representation of a cross-sectional view of a PCR chamber (1) having a tablet (9) during filling at section A-A' according to Figure 6B. The cavity (2) of the PCR chamber (1) comprises a tablet (9), that is immobilized in the cavity (2) and that engages the top layer (7) and the bottom layer (8). The rest of the cavity (2) of the PCR chamber (1) not comprising the sample S and the tablet (9) is filled with a gas (for example air).

[0029] Figure 8: is a schematic representation of a cross-sectional view of a fluid flow channel (25) which is filled with sample S, the channel comprising a valve (23) flanked by thinner parts (24) of the main body of a PCR disk (4). The channel is covered by a top layer (7) or bottom layer (8), depending on the location of the channel in the PCR disk. For ease of understanding only a channel with a top layer is depicted. The direction of the fluid flow is indicated by arrows without numbers. Figure 8A shows a valve in open configuration because of which the sample S can flow. The PCR disk is located in between a PCR device (22) and a detection device (21), which act as actuation devices (large, double arrows indicate directions of movement). The valve (23) is shown as an element protruding out of the outward surface of the main body of the reaction element, e.g. a PCR disk (4). Figure 8B shows the valve (23) in a closed configuration, closing the channel (25) and halting flow of sample S. The actuation devices have moved towards the PCR disk, in which the PCR device (22) moved upwards and the detection device (21) moved downwards, wedging the PCR-disk and thereby levelling the protruded part of the valve (23) with the outward surface of the reaction element, e.g. a PCR-disk, and translocating the valve towards the top layer (7), whereby the inner part of the valve engages the top layer (7), thereby closing the channel.

[0030] Figure 9: is a flow diagram of a microfluidic device (cartridge) production process.

[0031] DETAILED DESCRIPTION

[0032] Exemplary embodiments according to aspects of the present invention may satisfy one or more of the above-mentioned desirable features set forth herein. Other features and advantages will become apparent from the detailed description which follows.

[0033] In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the use of "or" means "and / or" unless stated otherwise. Furthermore, the use of the term "including", as well as other forms, such as "includes" and "included", is not limiting. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts.

[0034] The section headings used herein are for organizational purposes only, and are not to be construed as limiting the subject matter described. All documents cited in this application, including, but not limited to patents, patent applications, articles, books, and treatises, are expressly incorporated by reference in their entirety for any purpose. In the event that one or more of the incorporated literature and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls.

[0035] When referring to various directional relationships herein, such as, for example, downward, upward, left, right, top, bottom, etc., such relationships are referred to in the context of the orientation of the drawings, unless otherwise specified. It should be understood, however, that the devices in actuality may be oriented in directions other than those illustrated in the drawings and directional relationships would vary accordingly.

[0036] Reference will now be made to various embodiments, examples of which are illustrated in the accompanying drawings. However, it will be understood that these various embodiments are not intended to limit the disclosure. On the contrary, the disclosure is intended to cover alternatives, modifications, and equivalents.

[0037] Immobilizing the dosage form in the microfluidic chamber by engaging with the flexible layers located on the top and / or bottom of the microfluidic chamber, which clinch or sandwich the dosage form between these layers, overcame the frequently encountered problems with preloaded dosage forms of obstructing and clogging of the outlet channels when the fluid sample enters the microfluidic chamber as well as of the unpredictable advancement of a meniscus by a traveling sample fluid through the cavity of a microfluidic chamber. In exemplary embodiments, Figure 1 and Figure 2 show sectional views of microfluidic chambers without a dosage form and with a dosage form, respectively.

[0038] Figure 1 shows a sectional side view of an exemplary microfluidic chamber (1) without a dosage form. The microfluidic chamber (1) comprises a top layer comprising a first flexible, preferably transparent, material (7) and a bottom layer comprising a second flexible, preferably transparent, material (8), wherein the top layer and the bottom layer oppose each other. The walls (3) of the microfluidic chamber having a first surface (5) and a second surface (6), wherein the first surface (5) of the wall is affixed (mounted) to the top layer (7) and the second surface of the wall (6) is affixed (mounted) to the bottom layer (8), and wherein the top layer (7), bottom layer (8), and wall (3) form a cavity (2) of the chamber. In an embodiment, the first and second flexible material are respectively affixed to the first surface (5) and a second surface (6) of the walls (3) of the microfluidic chamber (1) via welding (10). The welding circumference or perimeter Pw is localized outward from the cavity perimeter Pc, i.e. Pw > Pc, typically to not compromise the walls (3) lining the cavity (2). In an embodiment, the first flexible material (7) and second flexible material (8) are affixed to the first surface (5) and a second surface (6) of the walls (3) of the PCR chamber (1), respectively, via gluing. In general, the glue can be placed closer to the perimeter of the cavity (2) than the welding circumference (10), even onto the perimeter (Pc) of the cavity (2).

[0039] Figure 2 shows a sectional view of a microfluidic chamber (1) according to Figure 1, wherein the cavity (2) of the chamber comprises a tablet (9), that is immobilized in the cavity (2) and that engages the top layer (7) and the bottom layer (8). In this embodiment, the first layer (7) and second layer (8) are respectively affixed to the first surface (5) and a second surface (6) of the walls (3) of the microfluidic chamber (1) via welding, of which the welding circumference is localized outward from the perimeter of the cavity. As can be seen in Figure 2, the height (17) of the tablet (9) is slightly larger than the height (18) of the walls (3) of the microfluidic chamber (1). Since the top layer consists of a flexible material (7) that is affixed to the first surface (5) of the wall (3) and the bottom layer consists of a flexible material (8) that is affixed to the second surface (6) of the wall (3), engagement of the tablet (9) with the top layer and the bottom layer stretches the first flexible material (7) and the second flexible material (8), thereby immobilizing the tablet (9) within the cavity (2). Although not shown in Figure 2, it will be appreciated that only one layer, i.e. either the top layer or the bottom layer is to be made of a flexible material, while still immobilizing the dosage form in the PCR chamber according to the invention.

[0040] Accordingly, in an embodiment, the invention relates to a microfluidic chamber, configured to be loaded with a sample fluid, such as a biological sample, comprising: a top layer comprising a first material; a bottom layer comprising a second material; wherein the top layer and the bottom layer oppose each other; wherein at least one of the first material and the second material is flexible; and wherein at least one of the first material and the second material is transparent; a wall having a first surface and a second surface; wherein the first surface of the wall is affixed to the top layer and the second surface of the wall is affixed to the bottom layer, and wherein the top layer, bottom layer, and wall form a cavity of the chamber; an inlet in the wall; an outlet in the wall, and a dosage form, preferably a tablet, that is immobilized in the cavity and that engages the top layer and the bottom layer; wherein engagement with the top layer and the bottom layer immobilizes the dosage form within the cavity. In an embodiment, both the first and second material are transparent, e.g. optically transparent.

[0041] In a further embodiment, both the first and second material are flexible.

[0042] In various exemplary aspects, the microfluidic device comprises a reaction element, such as a PCR disk (see Figures 3 and 4), defining a sample-distribution network having a main fluid channel (central channel, (14)) for supplying the sample fluid throughout the reaction element, one or more microfluidic or PCR chambers (preferably a plurality of such chambers), one or more inlet channels providing flow communication between each of the one or more microfluidic chambers and the main fluid channel, and one or more outlet channels in flow communication with one or more further chambers such as detection chambers or waste chambers. According to various embodiments, various types of valves can be arranged between the microfluidic chambers and the channels, loading mechanisms, detection and / or waste chambers that may be included in or on the reaction element. The valves can be selectively opened and closed to manipulate fluid movement through the reaction element, for example, with the assistance of a centrifugal force or positive displacement. In various exemplary embodiments, the one or more microfluidic chambers may be configured to receive an analyte-specific reagent effective to react with a selected analyte, e.g. a nucleic acid, that may be present in a sample fluid that fills the microfluidic chamber. According to an embodiment, the reaction element without the top and bottom layer is precast, preferably a precast plastic.

[0043] Figure 3 shows a photograph of a PCR disk (4) containing 5 PCR chambers (1) aligned radially from the waste chamber (11), each PCR chamber (1) with inlet channels (19) and outlet channels (20), and the top layer comprising a first, flexible, transparent material (7) (indicated as top foil) and the centrally located waste chamber (11). The PCR chambers (1) are filled with a gas (for example air). The outlet channels (20) are in fluid connection with the waste chamber (11). The central channel (14) is in fluid connection with all of the inlet channels (19) of the PCR chambers (1). The reaction element (here a PCR disk (4)) is configured to direct the sample fluid S from the central channel (14) to the plurality of inlet channels (19) forming a meniscus M that enters the PCR chambers (1) at the inlet opening (12) formed at the junction of the inlet channel (19) with the PCR chamber (1). The further progression of the meniscus M and sample fluid S as it begins to load each of the PCR chambers (1) advances in a substantially uniform manner and approaches the outlet (13) openings leading to the outlet channels (20), thereby pushing the gas through the outlets (13) opening leading to the outlet channels (20) towards the waste chamber (11). The result is therefore a complete filling of the PCR chambers (1) with the sample fluid S. In an embodiment, the microfluidic device comprising at least one microfluidic chamber, wherein said at least one microfluidic chamber is in fluid connection with a central channel.

[0044] Figure 4 shows a photograph of a PCR disk (4) according to Figure 3, in which one PCR chamber (1) comprises a tablet (9), which is immobilized within the cavity (2) by engaging with the top layer comprising the first flexible, transparent material (7) and the bottom layer comprising the second flexible, transparent material (8).

[0045] As used herein, the term "microfluidic device" is to be understood as a self-contained assembly of chamber(s) and / or channel(s), which is formed as a single object that can be transferred or moved as one fitting inside or outside of a larger instrument that is suitable for accepting and / or connecting to such microfluidic device. A microfluidic device and its instrument can be seen as forming an automated system, also referred to also as an automated platform. Some parts contained in the microfluidic device may be firmly connected whereas others may be flexibly connected and movable with respect to other components of the microfluidic device. The microfluidic device shall be understood as including at least one chamber or channel suitable for treating, processing, discharging, or analyzing a liquid, preferably a sample fluid. In the present context, the terms "liquid" and "fluid" are used interchangeably, unless the context requires otherwise. A microfluidic device can preferably perform several microfluidic functions (e.g., capillary valving, pumping, and / or sequence flowing). An example of such microfluidic device is given in W02007 / 004103. The microfluidic device may comprise a reaction element, such as a "PCR-disk", which is a unit of the microfluidic device comprising at least one but preferably more than one, such as 2, 3, 4 or more microfluidic chambers. Preferably, the PCR-disk is manufactured as a separate entity, which after manufacturing is fastened or paired to the rest of the microfluidic device (cf. Flow diagram of Figure 9). In the context of a microfluidic device, the terms "downstream" and "upstream" can be defined as relating to the direction in which fluids flow in such microfluidic device. Namely, a section of a fluidic path in a microfluidic device from which a fluid flows towards a second section in the same microfluidic device is to be interpreted as positioned upstream of the latter. Analogously, the section to which a fluid arrives later is positioned downstream with respect to a section which said fluid passed earlier. In general, as used herein the terms "fluidic" or sometimes "microfluidic" refers to systems and arrangements dealing with the behavior, control, and manipulation of fluids that are geometrically constrained to a small, typically (sub-)millimeter scale in at least one or two dimensions (e.g. width and height) or three dimensions, such as a channel. Such small-volume fluids are moved, mixed, separated or otherwise processed at microscale requiring small size and low energy consumption. Microfluidic systems include structures such as micro- pneumatic systems (pressure sources, liquid pumps, microvalves, etc.) and microfluidic structures for the handling of micro-, nano- and picoliter volumes (microfluidic channels, etc.). Exemplary and very suitable in the present context fluidic systems were described in EP1896180, EP1904234, and EP2419705, which are all incorporated herein in their entirety by reference.

[0046] As used herein, the term "automated system" refers to an integrated platform comprising an instrument and disposable material, such as plastics and solutions, for instance a microfluidic device, which the system uses in an automated manner to complete a certain process. Such process can be initiated by a user but throughout its automated processing within the system, the user's intervention is not necessary until the process' completion. As used herein the term "instrument" is to be understood as a machine equipped with a user interface (e.g. comprising at least a start button or an electricity plug), and / or an onboard computer with software, and programmed to perform certain functions, such as, for instance, running an assay, which can e.g. involve mixing, sonication, heating, cooling, excitation, data detection and collection, and possibly analysis, etc. Preferably, controlled heating and cooling via a heat exchanger of microfluidic chambers is performed by a separate unit of the instrument, commonly known as a PCR device. In an embodiment, the interface can be in the form of a console comprising a computer system running user interface software capable of initiating tests, displaying test results, and communicating with external information systems. An exemplary automated system capable of readily accommodating the present system and methods is diagnostic platform Idylla™ manufactured by Biocartis NV, which uses a disposable reagent-bearing microfluidic device that is engageable with a microfluidic device-processing instrument and provides sample-to-result analytical performance.

[0047] In line with the above, the term "chamber" is to be understood as any functionally defined compartment of any geometrical shape within a fluidic or microfluidic assembly, e.g. a microfluidic device, defined by at least one wall, and comprising the means necessary for performing the function attributed to this compartment. In an embodiment, the chamber comprises at least one wall and possibly a ceiling and a floor, wherein the wall, ceiling and floor can be composed of a single type of material or of different types of materials. For instance, the material forming the wall can be different from the material(s) forming the ceiling, such as a top layer, and / or the floor, such as a bottom layer. The term "microfluidic chamber" denotes the elements forming a space or cavity in a microfluidic device, and which is configured to enable a sample fluid to undergo chemical, physical, and / or biological reactions, requiring heat, (UV) light, sound and / or time to activate the reaction. A preferred biological reaction is polymerase chain reaction (PCR), in which a targeted nucleic acid molecule, such as a DNA molecule, is amplified. In the present invention, the terms "microfluidic chamber" and "PCR chamber", including the plural versions, are used interchangeably herein, unless the context requires otherwise. In other words, a PCR chamber is not limited to polymerase chain reactions but enables a sample fluid to undergo any chemical, physical, and / or biological reactions, requiring heat, (UV) light, sound and / or time to activate the reaction, unless the context indicates otherwise. In a preferred aspect, each of the microfluidic chambers in a reaction element, such as a PCR-disk, can be controlled and run chemical, physical, and / or biological reactions independent from the other microfluidic chambers in the reaction element.

[0048] In a preferred embodiment, the cavity of the microfluidic chamber is formed by a top layer, a bottom layer, wherein the top layer and the bottom layer oppose each other, and a wall having a first surface and a second surface, wherein the first surface of the wall is affixed to the top layer and the second surface of the wall is affixed to the bottom layer. Preferably, the cavity is a closed space comprising an inlet and outlet in the wall, wherein entrance and exit of liquids and / or gases can be controlled via the inlet and outlet in the wall, respectively.

[0049] In an embodiment, the top layer and / or the bottom layer of the microfluidic chamber is brought in close contact with a PCR device for controlled heating and cooling. For instance, active heating and cooling can be accomplished by mounting a heat exchanger beneath and / or above the microfluidic chamber for temperature control, as is commonly known in the art. The heat exchanger(s) can be transparent.

[0050] The result of the PCR, e.g. a PCR product, can be monitored or detected downstream of the microfluidic chamber. Preferably, however, a PCR product is monitored or detected in the microfluidic chamber. The most common methods for the detection of PCR products in microfluidic devices use fluorescent dyes, emitting light after excitation, and requiring at least a fluorescence detection mechanism. According to various embodiments, the top layer and / or the bottom layer are optically transparent, e.g. allowing light from various or only one wavelength(s) to pass through, such that the microfluidic chamber has a transparent window (cf. Figures 3 & 4) through which the fluorescent dyes can be excited and / or analytespecific reaction products, e.g. PCR products, can be detected, for example via fluorescence detection mechanisms. A detection device comprising an optical sensor for signal detection and / or an optical emitter for exciting fluorescent moieties can be a part of the instrument.

[0051] In a preferred embodiment, the top layer and / or the bottom layer of the microfluidic chamber are in close contact with both a heat exchanger, such as e.g. a PCR device, and a (fluorescence) excitation / detection mechanism, e.g. the detection device. For instance, the whole or part of the reaction element, such as a microfluidic chamber can be incased, such as wedged or clamped, between a heat exchanger and a detection device, such as a fluorescence excitation / detection mechanism. In another embodiment, the microfluidic chamber can be incased, such as wedged or clamped, between heat exchangers, which are located above and beneath the top layer and bottom layer, respectively, and wherein at least one of the heat exchangers is made of rigid, transparent material, on which a detection device can be installed. In a further embodiment, both heat exchangers are made of rigid, transparent material and an emitter can be installed above and a detector can be installed below the heat exchangers or vice versa.

[0052] According to another embodiment an optically transparent window is located on top, on the bottom or both on top and bottom of the cavity of the microfluidic chamber. Preferably, both the top layer and bottom layer of the microfluidic chamber are optically transparent, e.g. allowing light from various or only one wavelength(s) to pass through, e.g. wavelengths in UV, visible and IR spectrum, such as wavelengths from 200 nm - 1 mm, preferably between 380 nm - 760 nm. The transparent window can be configured of rigid or flexible transparent material, but the invention requires that at least one of the top layer or the bottom layer of the microfluidic chamber comprises flexible material.

[0053] Commonly used rigid material for an optically transparent window is glass, silicon-glass and cyclic olefin copolymer (COC). Preferably, the flexible, optically transparent material is chosen from flexible materials such as, for instance, polydimethylsiloxane (PDMS) or thermoplastic materials, preferably chosen from polyolefin-films (e.g. polyethylene (PE), polypropylene (PP), polybutylene (PB), polyisobutylene (PIB), ethylene vinyl acetate (EVA) or copolymers of ethylene with acrylate esters), polyester-, polyurethane- and COC-film, composite materials or any combination thereof, such as, e.g. a combination of polyester and PP. Various manufacturers provide suitable materials such as ThermalSeal RTS™ Sealing Films or SealPlate® films by Merck or Clear Weld Heat Seal series by Azenta. It is in the common knowledge of the skilled artisan to choose the material for the top layer and bottom layer that is suitable for the required biological, chemical and / or physical reaction and / or detection.

[0054] In this regard, the term "flexible" refers to an inherent property of a material and means the extent to which a material resists deformation in response to an applied force and regain its original shape and dimensions when the deforming force is removed. Flexibility is typically measured in newtons per (centi)meter (N / (c)m), and depends on the constituent material. It will be appreciated that the force applied to a flexible material, e.g. when immobilizing the tablet, may not result in permanent deformation of the material. Preferably, the tear force of the films is between 500N / cm - 5N / cm, and the temperature resistance between -80°C to 140°C. In a preferred embodiment, the top layer comprises flexible transparent material and / or the bottom layer comprises flexible transparent material, even more preferably both the top layer and the bottom layer comprise flexible transparent material, which can be the same or different, but preferably the same.

[0055] The top layer and / or the bottom layer can cover the entire reaction element (cf. Figs. 3 and 4) or only functional parts thereof, such as, for instance, channel(s), waste chamber(s) and / or valve(s), but at least PCR chamber(s).

[0056] As used herein, the term "affixed" or "affixing" refers to fastening or attaching a component to another component, preferably irreversibly. The top layer and bottom layer can be affixed to the first surface and second surface of the wall, respectively, by any means commonly known to the skilled artisan, but compatible with the materials used. Commonly used affixing procedures are anodic bonding, thermal fusion bonding, such as welding, and adhesion bonding, such as gluing. Many polymers are thermally bonded at temperatures above their glass transition temperatures (Tg), i.e. the temperature at which the polymer begins to soften.

[0057] Physical modification of the microfluidic chamber to immobilize the dosage form, such as by adjusting the interior shape of the chamber or introducing clamping features to control the location of the dosage form, should not distort further processing, such as excitation and / or detection, by blocking even partially the optical rays. Chemical modification to control the location of the dosage form might potentially prevent distortion of the light rays, but would introduce extra components, that potentially influence the chemical, physical, and / or biological reactions, such as PCR, and / or excitation and detection.

[0058] It was demonstrated by the present inventor that by engaging the top layer and bottom layer of the microfluidic chamber the dosage form could effectively be immobilized in the cavity, such that the dosage form does not move in the microfluidic chamber but remains at a fixed location by normal use of the microfluidic device, such as during transport or handling by the end-user. For "normal use" the skilled person can for instance consult the instructions for use.

[0059] According to an embodiment, the dosage form such as a tablet (9) is immobilized in the cavity (2) by the top layer (7) and the bottom layer (8) without an additional physical structure and without chemical action. According to another embodiment, the dosage form such as a tablet (9) is not attached to and / or dried onto the top layer (7) or the bottom layer (8). In a preferred embodiment, the top layer (7) and the bottom layer (8) directly contact the dosage form such as a tablet (9) and hold the dosage form such as a tablet in a defined position within the cavity (2) of the microfluidic chamber (1).

[0060] In an exemplary and preferred embodiment, the wall (3) of the microfluidic chamber (1) has a first height (18) between the first surface (5) and the second surface (6), and the dosage form (9), e.g. a tablet, has a second height (17) that is greater than the first height (18). In a preferred embodiment, the height ratio of the dosage form (9), such as a tablet, to the wall (3) is larger than 1, such as >1.05, >1.1, >1.15, >1.2, >1.3 or even >1.4, such as about 1.5.

[0061] According to a preferred embodiment, engagement with the dosage form, such as a tablet, (9) forces the top layer (7) to protrude above the first surface (5) of the wall (3). According to another embodiment, engagement with the dosage form, such as a tablet (9), forces the bottom layer (8) to protrude below the second surface (6). According to an embodiment, engagement with the dosage form, such as a tablet, forces the top layer and the lower layer to deflect away from each other.

[0062] It is contemplated that a variety of techniques may be used to fill the microfluidic chambers and other liquid-containment portions of the device, according to various aspects. For example, filling the various microfluidic chambers and other liquid-containment portions of the device may occur via centrifuging (e.g., spinning) the device to cause the sample fluid or other liquid to move from, for example, fluid channels into microfluidic chambers. Vacuum also may be used to cause the sample fluid in the device to move to and / or through various microfluidic chambers and other sample-containment portions. According to another exemplary aspect, a positive pressure, applied, for example, via a syringe, pump, or compressor placed in flow communication with a microfluidic chamber (e.g., a main fluid channel leading to an inlet channel) of the device may be used to cause liquid to move throughout the network of channels in the device to desired portions of the device. In yet another exemplary aspect, capillary forces may be used to move the liquid, such as the sample fluid, to desired microfluidic chambers and other samplecontainment structures of the device. Those having skill in the art would understand how to implement the various techniques discussed above to fill microfluidic chambers.

[0063] The microfluidic chambers may include a physical modification capable of substantially preventing the entrapment of a gas bubble within the microfluidic chamber during a sample fluid loading procedure. For example, the microfluidic chamber may include a physical modification or a shape configured so as to passively control (e.g., as opposed to actively controlling the pressure or other forces used in flowing the liquid to the chamber) the movement of fluid as it fills the chamber. In other words, the shape of the Y1 microfluidic chamber or the microfluidic chamber may be modified physically so as to achieve a desired movement of the sample fluid meniscus within the chamber, for example, by achieving a substantially uniform rate and / or manner of movement of the meniscus during loading.

[0064] According to an exemplary aspect, the inlet opening (12) and / or the outlet opening (13) may include differing transitions, for example, differing radii sizes and / or differing shapes. According to a further aspect, the inlet opening (also referred to as "inlet" or "inlet port" herein) and the outlet opening (also referred to as "outlet" or "outlet port" herein), which is formed at the junction between the outlet channel with the microfluidic chamber, are in smooth transition with the microfluidic chamber. According to a further embodiment, relative to the centre of the microfluidic chamber, the inlet opening and the outlet opening can be in any angle, e.g. from immediate adjacent, to 45°, 60°, 90° (perpendicular) 180° (opposite) or any acute or obtuse angle. In a preferred embodiment, the inlet port and the outlet port of the microfluidic chamber are located in an angle of about 180° + 10°. According to a further aspect, the microfluidic chamber can comprise one or two projecting members (protrusions; 15), which are configured to control the meniscus formation M of the sample fluid S entering the cavity (2) of the PCR chamber (1). By adjusting the presence and / or length of the projecting members (15) the skilled artisan can direct the preferred movement of the sample fluid S when filling the cavity (2). In an exemplary embodiment, the microfluidic chamber (1) comprises an inlet opening and an outlet opening in an angle of <180°, and one projecting member (15), which is located at the side of the inlet opening closest to the outlet opening. The terms "projecting member(s)" and "protrusion(s)" are used interchangeably herein.

[0065] Figure 5 shows a top sectional view of a PCR chamber (1), located in the main body of a PCR disk (4), wherein the cavity (2) of the chamber comprises a tablet (9), that is immobilized in the cavity (2) and that engages the top layer (7) and the bottom layer (8) (not shown). The PCR chamber (1) has an inlet (19) and an outlet (20) channel. The walls of the PCR chamber are indicated by (3). Arrows (without numbers) denote the direction of the fluid flow. The PCR chamber (1) is filled with a gas (for example air). The outlet channel (20) is in fluid connection with the waste chamber (11) (not shown). The inlet channel (19) is configured to direct the sample fluid S to enter the PCR chamber (1) at the inlet (12) opening formed at the junction of the inlet channel (19) with the PCR chamber (1), forming a meniscus M. The further progression of the meniscus M and sample S as it begins to load the cavity (2) of the PCR chamber (1) advances in a substantially uniform manner and approaches the outlet (13) opening leading to the outlet channel (20), thereby pushing the gas through the outlet (13) opening leading to the outlet channel (20) towards the waste chamber (11). The result is therefore a complete filling of the PCR chamber (1) with the sample fluid S.

[0066] Figure 5A shows an exemplary embodiment of a top sectional view of a PCR chamber (1) according to Figure 5, in which the inlet (12) opening formed at the junction of the inlet channel (19) with the PCR chamber (1) has two projecting members (15) pointing inwards of the cavity (2), which facilitate controlling meniscus formation while loading the sample fluid. In this case the outlet opening is located opposite to the inlet opening (cf. Figure 6).

[0067] Figure 5B shows another exemplary embodiment of a top sectional view of a PCR chamber (1) according to Figure 5, in which the inlet (12) opening formed at the junction of the inlet channel (19) with the PCR chamber (1) has one projecting member (15) pointing inwards of the cavity (2), which facilitate controlling meniscus formation while loading the sample. In this case the outlet opening is located at an angle of about 90° + 10° relative to the inlet opening on the side of the projecting member.

[0068] Figure 6 shows a series of top sectional views of a PCR chamber (1), located in the main body of a PCR disk (4), while being filled with a sample fluid S and meniscus M. The PCR chamber (1) comprises a cavity (2) comprising a tablet (9), that is immobilized in the cavity (2) and that engages the top layer (7) and the bottom layer (8) (not shown). The walls of the PCR chamber are indicated by (3). The PCR chamber (1) has an inlet channel (19) and an outlet channel (20). The PCR chamber (1) is filled with a gas (for example air). The inlet (12) opening formed at the junction of the inlet channel (19) with the PCR chamber (1) has two projecting members (15) pointing inwards of the cavity (2). The outlet channel (20) is in fluid connection with the waste chamber (11) (not shown). The inlet channel (19) is configured to direct the sample fluid S to enter the PCR chambers (1) at the inlet (12) opening formed at the junction of the inlet channel (19) with the PCR chamber (1), forming a meniscus M (Figure 6A). Arrows (without numbers) denote the direction of the fluid flow. The further progression of the meniscus M and sample fluid S as it begins to load the cavity (2) of the PCR chamber (1) advances in a substantially uniform manner and approaches the tablet (9), after which the sample fluid S advances at both sides of the tablet (9) with two menisci Ml and M2 (Figure 6B). In Figure 6C, the two menisci Ml and M2 progress at about the same rate in the cavity, pushing the gas in front of them towards the outlet (13) opening leading to the outlet channel (20) and towards the waste chamber (11) (not shown). Figure 6D shows a cavity (2) that is completely filled with sample fluid S and tablet (9). To ascertain complete loading of the cavity and allowing some recoil, for instance due to temperature changes during PCR, the PCR chamber (1) can be overfilled, in which part of the sample fluid S enters the outlet channel (20) (see Figure 6E), which can subsequently be sealed, e.g. with valves (not shown).

[0069] Figure 7 is a schematic representation of a cross-sectional view of a PCR chamber (1) having a tablet (9) during filling at section A-A' according to Figure 6B. The cavity (2) of the PCR chamber (1) comprises a tablet (9), that is immobilized in the cavity (2) and that engages the top layer (7) and the bottom layer (8). The rest of the cavity (2) of the PCR chamber (1) not comprising the sample fluid S and the tablet (9) is filled with a gas (for example air). Progression of sample fluid S results in filling all spaces as it begins to load the cavity (2) of the PCR chamber (1). The result is eventually a complete filling of the cavity (2) of the PCR chamber (1) with the sample fluid S and the tablet (9).

[0070] The properties of the sample fluid being loaded into the chamber, such as, for example, viscosity, surface tension, density, and / or other fluid properties may influence the progression of the meniscus. Nonetheless, moving the sample fluid within a range of optimal flow rates (e.g., actively controlling the sample flow), for example, by filling the microfluidic device using a substantially uniform pressure, may make the progress of the sample fluid in the microfluidic chamber more uniform, thereby decreasing the chances of trapping air.

[0071] The term "channel" or "channel system" as used in the present invention means a closed conduit or pipe through which a fluid flow can be directed, for example to a PCR chamber, cavity, and / or waste chamber located in the reaction element. Preferably a circuit of channels is precast, etched or generated by laser- induced ablation in the backing layer (main body) of the reaction element, i.e. the reaction element without the top and bottom layers. Subsequently, the circuit of channels are covered by a flexible membrane, such as the top layer or the bottom layer, forming a closed conduit or pipe, in which the fluid or gas is confined by the channel walls.

[0072] Valves may be arranged in the channels of the reaction element to control fluid and gas flow in the channels. Valves may be introduced in the channel(s) upstream of the PCR chamber, such as, for instance, in the main fluid channel or in the inlet channel(s) of each PCR chamber. Valves may be introduced in the channel(s) downstream of the PCR chamber, such as, for instance, in the outlet channel(s). As used herein, a "valve" is a device or means that regulates, directs, or controls the flow of fluids and gases by opening, closing, or partially obstructing passageways, such as channels. When loading a PCR chamber with a sample S and pushing gas out, the valves are in an open configuration. When a PCR chamber is overloaded with sample such that part of the sample entered the outlet channel (cf. Figure 6E), the valves can be closed. In a closed state, the valve(s) prevents fluid and / or gas flow through the channel(s). Closed

[0073] PCR chambers are thus created which allow a better control of PCR conditions.

[0074] Another advantage of valve(s) arranged in the channel(s) of the reaction element is that the actuating element(s) does not contact the fluid sample. Thus, the actuating element(s) is not contaminated with a fluid, e.g. fluid sample, so that the actuating element(s) can be used again.

[0075] Figure 8 shows a schematic representation of a cross-sectional view of a channel (25) which is filled with sample S, the channel comprising a valve (23) flanked by thinner parts (24) of the reaction element, e.g. a PCR disk (4). In Figure 8, a top layer (7) is shown covering the channel (and the reaction element). For the sake of simplicity, a bottom layer is not shown. The height of the valve is larger than the cross-section or height of the reaction element comprising the channel. The valve and the thinner parts can be made of the same material as the rest of the reaction element, which reduces manufacturing costs. Although not necessary for actuating the valve per se, the thinner parts are intended to facilitate movement of the valve when the actuation elements translocate the valve's position relative to the channel and the remainder of the reaction element. The skilled artisan will appreciate that other configurations of the valve are possible. In this respect, a valve being covered on the exterior by a fastened, flexible bottom layer preventing leakage, simplifies design choices, such as the absence of an extra sealing of the valve. The valve normally has a form and dimensions in function of the width and form of the channel. Nonetheless, it can have any form provided it enables substantially halting fluid and gas flow when in a closed configuration.

[0076] During operation, the reaction element comprising the microfluidic chambers is brought in close contact with both heat exchangers of a PCR device or a heat exchanger of a PCR device and a detection device mechanism, via e.g. wedging or clamping the reaction element between the heat exchanger(s) and the detection device, which act as actuation means.

[0077] Figure 8A shows a valve in open configuration because of which the sample S can flow (indicated by small arrows without numbers), e.g. to fill the PCR-chambers. The valve (23) is shown as an element protruding out of the outward surface of the reaction element, e.g. the PCR-disk (4). The reaction element, e.g. a PCR disk, is located in-between a heat exchanger, e.g. a PCR device (22) and a detection device (21). The large, double arrows indicate directions in which the heat exchanger and the detection device can move. Figure 8B shows the valve (23) of Figure 8A, but now in a closed configuration, closing the channel and halting flow of sample S. The actuation devices have moved towards the PCR-disk, in which the heat exchanger, e.g. a PCR device (22) moved upwards and the detection device (21) moved downwards, wedging the reaction element, e.g. a PCR-disk, and pushing the valve inwards of the channel, thereby levelling the protruded part of the valve (23) with the outward surface of the reaction element, e.g. a PCR-disk. As a result, the inner part of the valve facing the channel is translocated towards the top layer (7), thereby closing the channel. The thinner parts (24), which connect the main body of the reaction element (4) to the valve (23), facilitated movement of the valve relative to the reaction element. In the actuating process, when closing the channel, the thinner parts (24) have also moved towards the top layer (7).

[0078] In an embodiment, the present invention relates to a reaction element comprising at least one microfluidic chamber (1), said microfluidic chamber (1) comprising: a top layer (7) comprising a first material; a bottom layer (8) comprising a second material, wherein the top layer and the bottom layer oppose each other; a wall (3) having a first surface (5) and a second surface (6), wherein the first surface of the wall is affixed to the top layer and the second surface of the wall is affixed to the bottom layer, and wherein the top layer, bottom layer, and wall form a cavity (2) of the chamber; an inlet (12) in the wall; an outlet (13) in the wall; and optionally a dosage form, preferably a tablet, (9) that is immobilized in the cavity and that engages the top layer and the bottom layer, wherein engagement with the top layer and the bottom layer would immobilize the dosage form within the cavity, when present, and wherein at least one of the first material and the second material is flexible, and wherein at least one of the first material and the second material is transparent; and said reaction element further comprising at least one inlet channel (19, 25) for transporting a sample S to at least one microfluidic chamber (1), wherein said inlet channel comprising at least one valve, and / or said reaction element further comprising at least one outlet channel (20, 25) for expelling, such as air, from said one microfluidic chamber (1), wherein said outlet channel comprising at least one valve, and / or said reaction element further comprising at least one main channel (11, 25) for transporting a sample S to said at least one inlet channel (19), wherein said main channel comprises at least one valve.

[0079] In an embodiment, the present invention relates to a method for operating a reaction element as described herein, wherein said reaction element is wedged between a heating element, such as a PCR device, and a detection element, wherein a valve is closed by said wedging, thereby operating said reaction element.

[0080] According to yet further exemplary embodiments, the overall shape of the microfluidic chamber may be modified so as to assist in avoiding bubble entrapment during filling. For example, the shape of the microfluidic chamber may be changed from having a substantially circular cross-sectional configuration to a more elongated shape, such as, for example, an oval-like (e.g., elliptical) cross-sectional configuration. Narrowing the dimensions of the microfluidic chamber in the direction substantially perpendicular to the direction of flow of the sample fluid through the microfluidic chamber (in other words elongating the chamber substantially in the direction of the sample flow), while substantially maintaining the volume of the chamber, the meniscus of the sample fluid may move through the microfluidic chamber and surround the tablet in a substantially uniform manner such that the entire menisci Ml and M2 come together in one meniscus M which reaches an outlet of the microfluidic chamber. Preferably, the microfluidic chamber is ellipsoidal, even more preferably the microfluidic chamber is ellipsoidal in which one part is rounded, e.g. has a constant radius, and comprises an inlet port or outlet port, and another part of the microfluidic chamber is tapered from the round part towards an inlet or outlet port. In another embodiment, the microfluidic chamber is circular, i.e. has about a constant radius (apart from the inlet or outlet port).

[0081] Preferably, the size and shape of the dosage forms, such as tablets are adjusted vis-a-vis the size and shape of the microfluidic chamber. The size and shape of the dosage form, such as a tablet, should be fitting into the microfluidic chamber, but for the height of the dosage form, such as a tablet, which should be larger than the height of the wall of the microfluidic chamber. Next, the size of the dosage form, such as a tablet, should not obstruct removal of the air bubble upon filling of the microfluidic chamber. In particular, the size of the dosage form, such as a tablet, should enable the sample fluid S and the air to flow pass it. In an embodiment, when filling the microfluidic chamber, the dosage form, such as a tablet, is preferably larger than the outlet port, i.e. the dosage form, such as a tablet, cannot pass through the outlet port into the outlet channel. In an embodiment, the size of the dosage form, such as a tablet, is adjusted to about a fraction of the radius of the microfluidic chamber, but at least smaller than the radius of the microfluidic chamber.

[0082] Preferably, the dosage form, such as a tablet, is immobilized in a location of the cavity which avoids obstruction of the inlet port and outlet port, enabling filling of the cavity with sample fluid S and expelling gas, e.g. air, from the cavity. In a preferred embodiment, the invention relates to a microfluidic chamber as described herein, wherein the dosage form, such as a tablet, partially fills the cavity. In another preferred embodiment, the dosage form, such as a tablet, (9) is positioned in about the center of the cavity (2). In another preferred embodiment, the center point of the dosage form, such as a tablet, (9) is about aligned with the center point of the cavity (2). In the latter arrangements, the location of the dosage form, such as a tablet, enables air and fluid to flow on both sides, while not obstructing the outlet port. In yet another preferred embodiment, the distance between the dosage form, such as a tablet, (9) and the inlet (12) is about the distance between the dosage form, such as a tablet, (9) and the outlet (13). In a further preferred embodiment, the dosage form, such as a tablet, (9) is not in contact with the inlet (12) and / or outlet (13). In another preferred embodiment, the present invention relates to a microfluidic chamber as described herein, wherein the circumference ratio of the dosage form, such as a tablet, to the cavity is smaller than 1, such as <0.9, <0.8, <0.7 or even <0.6, such as about 0.5.

[0083] In a particular preferred embodiment, the present invention relates to a method of combining reactants for a biological, chemical or physical reaction, such as a nucleic acid amplification reaction, in a microfluidic chamber, the method comprising:

[0084] (1) providing a microfluidic chamber according to the invention, for instance as described in claim 1;

[0085] (2) adding a sample fluid comprising a nucleic acid into the cavity via the inlet to contact the dosage form, such as a tablet; and

[0086] (3) dissolving the dosage form in the sample fluid to provide a reaction mixture, thereby combining the reactants for the biological, chemical or physical reaction, such as a nucleic acid amplification reaction.

[0087] In another particularly preferred embodiment, the present invention relates to a method of combining reactants for a biological, chemical or physical reaction, such as a nucleic acid amplification reaction, in a microfluidic chamber, the method comprising:

[0088] (1) providing a microfluidic chamber according to the invention, for instance as described in claim 1;

[0089] (2) adding a sample fluid comprising a nucleic acid and primers and / or probes into the cavity via the inlet to contact the dosage form, such as a tablet; and

[0090] (3) dissolving the dosage form in the sample fluid to provide a reaction mixture, thereby combining the reactants for the biological, chemical or physical reaction, such as a nucleic acid amplification reaction.

[0091] In a further preferred embodiment, the invention relates to a method as described herein, wherein, upon adding the sample fluid into the cavity, the dosage form remains immobilized until complete filling of the cavity with the sample fluid; and / or the fluid flows surround the immobilized dosage form until complete filling of the cavity with the sample fluid, preferably, the sample fluid generates a first meniscus Ml between the wall and a first side of the dosage form and a second meniscus M2 between the wall and a second side of the dosage form; and / or, wherein, upon adding the sample fluid into the cavity, the amount of air in the cavity upon complete filling of the cavity with the sample fluid is reduced by at least 70%, such as >80%, or even >90%, >95%, or >99%, or even 100%. In a further preferred embodiment, the invention relates to a method as described herein, wherein adding the fluid comprises flowing the fluid around at least a portion of the dosage form within the cavity. In a further preferred embodiment, the invention relates to a method as described herein, wherein the dosage form remains immobilized during the step of -starting- dissolving the tablet. In a further preferred embodiment, the invention relates to a method as described herein, wherein the dosage form, such as a tablet, is disintegrated before the step of dissolving the dosage form, such as a tablet.

[0092] In a further particularly preferred embodiment, the invention relates to a method of performing a nucleic acid amplification reaction, the method comprising:

[0093] (1) providing a microfluidic chamber according to the invention, for instance as described in claim 1;

[0094] (2) adding a sample fluid comprising a nucleic acid and optionally primers and / or probes, into the cavity via the inlet to contact the dosage form;

[0095] (3) dissolving the dosage form in the sample fluid to form a reaction mixture in the microfluidic chamber;

[0096] (4) amplifying the nucleic acid in the microfluidic chamber; and

[0097] (5) detecting the nucleic acid in the microfluidic chamber, thereby performing the nucleic acid amplification reaction.

[0098] The inventor found that the shape of the dosage form, e.g. tablet, is of lesser importance. Dosage forms, such as tablets, performed well with circular, ellipsoidal, wiggle, square, and diamond shapes, including parallelograms, but shapes obstructing the removal of the air bubble should be avoided, such as e.g. horseshoe shapes which could potentially trap some air and obstruct the dissolving of the dosage form, such as a tablet. Preferably, the dosage form, such as a tablet, is circular, which facilitates automation in the disposition of the dosage form, such as a tablet. In order to facilitate identification and / or correct localization, the dosage forms, such as tablets, may have an engravement. In addition or alternatively, the dosage forms, such as tablets, may be differently shaped for the individual PCR chambers.

[0099] As used herein, the term "dosage form" (also called "unit dose") is the product in the form in which it is deposited in the microfluidic chamber for use, with a specific mixture of active ingredients, such as PCR primers, probes, salts, enzyme(s), etc., and inactive components (excipients), e.g. in a particular configuration, and apportioned into a particular dose. Preferably, the dosage form, e.g. a tablet, comprises at least all the active ingredients, e.g. constituents to perform a (Reverse Transcriptase)-PCR and facilitate detection of the target product, such as, e.g. DNA polymerase(s), reverse transcriptase, deoxyribonucleotide triphosphates (dNTPs), primer(s) which can be labelled or not, probe(s), which can be labelled or not, and buffer-components (e.g. KCI, (Nl-UhSO^ MgCI2). In a preferred embodiment, the dosage form, e.g. a tablet, comprises polymerase, deoxyribonucleotide triphosphates (dNTPs), primers and probes. The particular constituents of the dosage form depend on the target to be detected and / or the manner of detection. Indeed, in another preferred embodiment, the dosage form, e.g. a tablet, comprises all the active ingredients, e.g. constituents to perform an (RT-)PCR and facilitate detection of the target product, such as, e.g. DNA polymerase(s), reverse transcriptase, (deoxy)ribonucleotide triphosphates (dNTPs), and buffer-components (e.g. KCI, (NH4)2SO4, MgCI2), while the primer(s), which can be labelled or not, and probe(s), which can be labelled or not, are administered to the sample fluid before the sample fluid enters the cavity via the inlet and thus before contacting the dosage form, for instance as described in the FLEX technology of W02022 / 090521 by Biocartis NV, which is incorporated herein in its entirety by reference. In addition, the dosage form can comprise common additives or co-solvents used as (RT-)PCR enhancers, in their recommended final concentrations.

[0100] Next to the active ingredients, the dosage form can comprise "inactive components" or "excipients", which facilitate achieving the format of the dosage form (e.g., facilitate freeze-drying), are helpful in storage, and / or are helpful in disintegrating the dosage form, e.g., help the dosage form into solution. Preferably, the active ingredients and the excipients are evenly distributed in the dosage form. This facilitates an even disintegration of the dosage form and reliability. As used herein, a "solution" is defined as an homogenous mixture of two or more components in which the molecules of one component is dissolved into the other, requiring complete miscibility between the components and creating a single phase mixture down to the molecular level. The dissolving substance is defined as the "solvent" while the dissolved substance is defined as "solute".

[0101] The "dosage form" can be solid or semi-solid. The "dosage form" according to the invention comes in various formats, such as, tablets, capsules, beads, pellets and granules. A tablet consists of one or more active ingredients and one or more excipients, usually in powder form, pressed or compacted from a powder into a solid dose. Tablets are prepared either by molding or by compression. A capsule is a dosage form usually made from gelatin and filled with an active ingredient and excipients. Two common capsule types are available: hard gelatin capsules for solid-fill formulations, and soft gelatin capsules for liquid-fill or semisolid-fill formulations. A granule is a dosage form consisting of powder particles that have been aggregated to form a larger mass, usually 2-4 mm in diameter. Granulation overcomes segregation of the different particle sizes during storage and / or administration into the microfluidic chamber. In a preferred embodiment, the dosage form is a tablet or a bead. Generally the dosage forms are prepared by freeze-drying methods, which are conducted in the presence of glass-forming agents and stabilisers for the structures formed as well as optionally fillers (see for example US Patent No. 5,250,429 , US Patent No. 5,763,157 and EP-0726310 ). Trehalose in particular has been used in PCR mixtures to assist in the stabilisation and also in non-freeze-dried formulations as a PCR enhancer. However, care needs to be taken in the selection of reagents used as glass-forming agents and stabilisers in these reaction mixtures to ensure that they do not interfere with or unduly inhibit the physical, chemical or biochemical reaction in which the compositions are required to take part. US2002 / 173016 relates to high throughput lyophilized polymerase devices and methods. W02008 / 075072 relates to use of a stabilised freeze-dried formulation in a biosensor. W02005 / 108620 discloses methods and systems for processing polynucleotides such as DNA. Becket et al. (Reactive & Functional Polymers (2004) 60:183-193) discusses detection of polyelectrolytes in water by fluorescence tagging. Davidson & Sun (Pharm. Res. (2001) 18:474-79) is a discussion of the effect of sucrose / raffinose mass ratios on the stability of co-lyophilized protein during storage. Riisom et al. (JAOCA (1980) 57:354- 359) discusses the effect of amino acids on the autoxidation of safflower oil in emulsions. The skilled person will appreciate the teachings of all of these references. When a composition is freeze-dried in the presence of a glass-forming reagent, it generally forms a "cake"-type 3-dimensional structure. This structure is optionally supported by the inclusion of a suitable stabiliser for the cake structure, and so this can be a further component of the mixture.

[0102] Examples of suitable stabilisers that may be included in the composition include polymeric compounds such as polyethylene glycol (PEG), polyvinylpyrrolidine (PVP) and or polysaccharides such as Ficoll or Dextran. In a particular embodiment, however, the stabiliser is omitted from the composition as it has been found that compounds such as PEG may contribute to the inhibition of fluorescent signals. In some cases, gelatine may be used to add stability to the cake. Examples of commonly known fillers are, e.g. starch, lactose, microcrystalline cellulose, StarLac, and Combi Lac. Examples of suitable binding agents are, e.g., Xanthan gum, methylcellulose, hydroxypropyl-methylcellulose, hydroxyethylcellulose and mixtures thereof.

[0103] It will be appreciated that the integrity of the dosage form during filling of the PCR chamber may facilitate the performance of the test. This may also be realized by providing the active ingredients in excess, because of which some loss due to, e.g. overfilling the PCR chamber, is compensated for. In a preferred embodiment, the dosage form dissolves minimally or does not dissolve during filling of the cavity, e.g. PCR chamber, but starts dissolving only after filling. Means for extending release of active ingredients, e.g. starting dissolving only after filling, are well established in the art, such as the use of coatings to regulate the dissolution process of a dosage form, e.g. to delay until the cavity, such as a PCR chamber, is completely filled. Coatings encompass the outer covering of a dosage form with a layer or substance. Suitable coating techniques include, for instance, electrostatic coating, dip coating, rotary-die coating, and film coating, all well known in the art.

[0104] Preferably, the active components of the dosage form are dissolved after complete filling of the cavity of the microfluidic chamber, and made available to enable a sample fluid to undergo chemical, physical, and / or biological reactions. In this context, the term "dissolution" or "dissolving" refers to a process through which solutes, e.g. the active components in a dosage form, dissolve in a solvent, e.g. the sample fluid, to form a solution.

[0105] The dissolution time refers to the time needed to dissolve the dosage form, and can depend on its particular format. For instance, a semi-solid dosage form will generally dissolve faster than film-coated tablets and hard gelatin capsules.

[0106] In a preferred embodiment, the dosage form is disintegrated, which may facilitate dissolution. The dosage form preferably breaks down into small particles to expediate rapid release of the active ingredients so that the components are readily available to dissolve in the microfluidic chamber. The turnaround time ("TAT") can be decreased by disintegrating the dosage form before, during or after filling of the microfluidic chamber, thereby facilitating the dissolving process. Hence, the process of disintegration can integrate with dissolution where a solid substance, e.g. dosage form, disintegrates into small pieces while dissolving in a solvent, e.g. the sample fluid, until it forms a uniform solution of the solute and the solvent. In the present context, the terms "disintegration" and "to disintegrate" refers to a chemical or physical process in which a substance, e.g. dosage form, is broken into tiny fragments, particles and molecules. Disintegration of a substance can be used to improve its solubility (time). It is realized that a disintegrated dosage form also minimizes air entrapment. Thus, the dosage form can be disintegrated at various moments, e.g. (just) before, during or after filling of the microfluidic chamber. As mentioned herein, the dosage form may comprise an excess of ingredients to compensate for any loss in case of an overfill (the sample fluid entering the outlet channel), such as, for instance, when the dosage form is disintegrated before or during filling of the microfluidic chamber.

[0107] To maintain proper dissolution time a formulator can be used as a disintegrant. Also, the effects of fillers and binders can affect the rate of dissolution of a particular substance. Commonly used disintegrants are carbohydrates and other organic compounds, such as, for instance, crospovidone, microcrystalline cellulose, sodium starch glycolate, sodium carboxy methyl cellulose, pregelatinzed starch, carboxy methyl cellulose, and modified corn starch.

[0108] In an embodiment, the excipients of the dosage form comprise stabilisers, disintegrants and optionally fillers.

[0109] For instance, the composition of the dosage form can be adjusted such that dissolution of the dosage form starts after filling the microfluidic chamber. Timing the filling of the microfluidic chamber comprising a dosage form with a sample fluid is within the common knowledge of the skilled artisan, as is adapting the dissolution time of the dosage form by adjusting the various components. Reference is made to the examples. The dissolution time of the dosage form is preferably controlled and is more preferably as short as possible upon complete filling of the microfluidic chamber, which would decrease the TAT of the assay.

[0110] As described in the examples section, if deemed necessary, the skilled person can easily adjust the timing to start a subsequent process necessitating dissolution of the dosage form, such as a biological, chemical or physical reaction. For instance, the timing can be shortened or prolonged in function of the complete dissolution of the dosage form based on the particular dosage form, such as coating of the dosage form, after which the sample can undergo a chemical, physical and / or biological reaction, such as PCR.

[0111] In an embodiment, the dosage form such as a tablet has a dissolution rate of less than 5 minutes, 4 minutes, 3 minutes, or 2 minutes, such as less than 1.5 minutes, less than 1 minute or even less than 30 seconds. The term "dissolution rate" refers to the mean time necessary in which 50% of the active substances are dissolved. Preferably, at least 80% of the active ingredients in the dosage form are dissolved in less than 15 minutes, such as less than 10 minutes, or even less than 5 minutes, such as less than 4 min, less than 3 min, less than 2 min, or even less than 1 min. Even more preferably, at least 90% of the active ingredients in the dosage form are dissolved in less than 15 minutes, such as less than 10 minutes, or even less than 5 minutes, such as less than 4 min, less than 3 min, less than 2 min, or even less than 1 min, and most preferably, more than 99.5% of the active ingredients in the dosage form are dissolved in less than 15 minutes, such as less than 10 minutes, or even less than 5 minutes, such as less than 4 min, less than 3 min, less than 2 min, or even less than 1 min.

[0112] In a preferred embodiment, the dosage form is disintegrated by crushing. The term "crushing" refers to a physical process of disintegration, in which the substance, such as the dosage form, is broken down mechanically or manually into tiny fragments, particles and molecules. The crushing of a dosage form, e.g. a tablet, can be executed at various moments, but after manufacturing the microfluidic chambers comprising the dosage forms, e.g. after affixing the top layer to the wall of the microfluidic chambers.

[0113] In a preferred embodiment, the dosage form, such as a tablet, is crushed between the heat exchangers of a PCR device, between a detection device and a PCR device or is crushed manually. In another preferred embodiment, the dosage form, such as a tablet, is crushed before adding a fluid into the cavity, during filling or after filling the microfluidic chamber. In yet another preferred embodiment, the dosage form, such as a tablet, is crushed after transport, after storage, or after retracting the PCR disk from the housing of the microfluidic device, e.g. a cartridge. In a further preferred embodiment, the dosage form, such as a tablet, is crushed after transport, storage, or after retracting the PCR disk from the housing of the cartridge and before adding sample fluid into the cavity or filling the microfluidic chamber. In another embodiment, the dosage form, such as a tablet, is crushed after filling the microfluidic chamber.

[0114] The sample fluid is discharged outwards through the outlet after the cavity is completely filled with the sample fluid, the phenomenon that bubbles remain in the cavity due to incomplete exhaust is avoided, and therefore the detection effect of the sample fluid can be guaranteed. The microfluidic chamber can be overfilled with a sample fluid, i.e. the sample fluid enters the outlet channel, which would allow some recoil of the sample fluid but without any gas re-entering the microfluidic chamber. In an embodiment, the microfluidic chamber is overfilled with the sample fluid, and preferably enters the outlet channel. In a further embodiment, after the sample fluid entering the outlet channel, the outlet channel is closed, such as for instance by a valve.

[0115] A microfluidic device consists of multiple parts of which a number are standard to each device, but a number of parts are assay specific, such as, for instance, buffers and PCR components, e.g. primers and probes. The assembly of the different parts into a finished device requires a precise manufacturing process, in which all steps are interdependent and meticulously adjusted. A problem frequently encountered when redesigning even only one step of a production process is the necessity to remodel various other steps of the entire process as well. In addition, remodeling the machinery or even new machinery is required. Implementing a new process or adapting an existing process comes with a high cost, lengthy tests on the robustness of the process and on the robustness of the end-product, regular interruptions and training of personnel. Hence, this tampers with the routine production of microfluidic devices.

[0116] Figure 9 shows a flow diagram of a microfluidic device production process (indicated as Cartridge production), in which both the current process with a heat-drying step on the left hand side, and the invention with the dosage forms on the right hand side are depicted. The microfluidic device production process of the present invention can for a large part make use of the pre-existing methods and machinery. The main difference in the production process of the unpaired PCR disk is a separate step in which the dosage forms are deposited in the cavity (2) of the respective microfluidic chambers (1) of the semifinished PCR disk (PCR disk (4) with bottom layer (8)). Similar to the current process, the top layer (7) is subsequently affixed to the PCR disk (4). It will be appreciated that the term bottom layer in this context refers to the layer on which the dosage form is positioned in the semi-finished PCR disk, but not to the position of the PCR disk in the finished cartridge. The production of the Finished PCR Disks with dosage forms can be tested and optimized without interrupting the routine production of the microfluidic devices, shown on the left hand side of the flow diagram. Fastening or pairing the Finished PCR Disk to the main body of the microfluidic device results in the Finished microfluidic device ("Finished cartridge"), which can be packaged, stored and shipped. In an embodiment, the conventional process with heat-dried components in at least one microfluidic chamber (1) and the deposition of a dosage form, such as a tablet in a cavity (2) of at least one microfluidic chamber (1) are combined, resulting in a PCR disk comprising both heat-dried components and dosage forms such as tablets. In this case, it is preferred to conduct the heat-drying step before depositing the dosage forms, such as tablet(s), since the heat-dried components are less prone to disturbances when manipulating compared to a (yet) non-immobilized dosage form.

[0117] The invention thus relates to a method of manufacturing a microfluidic chamber (1) comprising: placing a dosage form, such as a tablet (9) on top of a surface of a first flexible, transparent material (7) that is affixed to a first surface of a wall (5), the wall (3) comprising an inlet opening and an outlet opening; affixing a second flexible, transparent material (8) to a second surface of the wall (6) such that the second flexible, transparent material (8) is over the dosage form, such as a tablet (9), and opposes the first flexible, transparent material (7), wherein the first flexible, transparent material (7), second flexible, transparent material (8), and wall (3) form a cavity (2) of the microfluidic chamber (1), and wherein the dosage form, such as a tablet (9), engages the first flexible, transparent material (7) and the second flexible, transparent material (8) and engagement with the first flexible, transparent material (7) and the second flexible, transparent material (8) immobilizes the dosage form, such as a tablet (9), within the cavity (2), thereby providing the microfluidic chamber (1) comprising an immobilized dosage form. Exemplary aspects of the disclosure provide a microfluidic device configured to be loaded with a (biological) sample for physical, biological and / or chemical testing. According to various exemplary embodiments, the present invention may provide a device useful for testing one or more sample fluids for the presence, absence, and / or amount of one or more selected analytes. The sample may be a biological sample, for example, an aqueous biological sample, an aqueous solution, a slurry, a gel, a blood sample, or any other type of sample.

[0118] For a variety of applications of microfluidic devices, including, for example, when using microfluidic devices for biological testing, reagents may be dried (e.g., "spotted") into sample-containment portions of the device so that when the devices are filled with a sample to be analyzed, the sample and the reagents may mix as the sample loads a sample-containment portion. Providing dried reagents may improve the stability of various components at room temperature, including, for example, proteins such as DNA / RNA polymerases. As used herein, the term "dried reagent" or variations thereof means liquid reagent where liquid has been at least partially removed by processes where the liquid reagent is, for example, lyophilized, freeze-dried, vacuum dried, or gas dried, for example, air dried, nitrogen dried, or dried by any other inert gas (not reacting or interacting with any reagent to be dried in the liquid reagent), where the gas can be at ambient temperature, heated, or cooled, for example, ambient air and / or the gas can be at ambient pressure or compressed, for example, compressed nitrogen, or forced, for example, forced air, by any means including, but not limited to, fan or blower. Further, portability of the microfluidic device and sensitivity of PCR may be additional advantages since dried reagents can be relatively easily stored and a sample solution containing PCR targets is not diluted when mixed with dried PCR reagents. For at least some of these various reasons, reagents are dried (deposited) in the chambers of microfluidic devices, such as, for example, microfluidic chips, trays, or cards.

[0119] EXAMPLES

[0120] Example 1 Comparing PCR results using standard heat-dried PCR mixes with PCR tablets

[0121] The inventor set out to compare the standard heat-dried PCR mixes with freeze-dried PCR mixes, which are subsequently pressed into mini-tablets according to standard procedures. In particular, to test the concept, first a PCR master-mix is made, which is used for heat-drying in the PCR-chamber or for freeze - drying and subsequently pressing tablets.

[0122] The PCR master solution contains (pl per 20pl final reaction volume) Tris pH 8.8 500mM 2.0pl

[0123] BSA 20mg / ml 0.25pl

[0124] Forward primer lOpM 2.0pl

[0125] Reverse primer lOpM 2.0pl

[0126] Taq polymerase 5 U / .1 filtered O.IGpl

[0127] Taqman® probe 2pM 2.0p.l

[0128] Water (DNase / RNase free) variable variable

[0129] These reagents are combined in a reaction tube. Before freeze-drying, "tablet-mix" comprising the PCR master solution, stabilisers and fillers, is snap frozen in liquid nitrogen. The very fast freezing rate minimizes the freeze concentration effect such as pH shift, common with slower freezing rates. Since a final moisture content in the range of 1-3% is desirable, the freeze-drying process includes a secondary drying phase once all the ice has sublimed. Subsequently, the mix is placed inside a freeze dryer (e.g. Virtis Advantage), which is previously chilled to +5°C and then set to carry out a standard program.

[0130] Analysis of the appearance of the freeze-dried cakes is made by visual inspection by the operator. For the tablets, the resultant freeze-dried mixes (cakes) are immediately pressed into cylindrical tablets using a small manual powder compacting press machine.

[0131] The dimensions of the tables are adapted to fit adequately into the PCR chambers, i.e. the diameter of the tablets is between 3-4 mm, which is less than the diameter of the PCR chamber (5.32 mm) and the height of the tablet is about 0.8-0.9 mm, which is less than the height of the PCR chamber wall (1 mm).

[0132] Next, the time to dissolve the tablets completely in sample fluid is determined. It is safe-guarded that this time period is respected before the actual PCR starts.

[0133] The tablets are placed in the PCR disk, and the top layer is affixed to the PCR walls. Subsequently, the unpaired PCR disk is subjected to standard PCR protocols, including the filling of chambers with sample liquid containing spiked DNA. For comparative reasons, e.g. avoiding differences in operation or between PCR disk production, the PCR disk comprises both PCR chambers with tablets and PCR chambers with standard heat-dried PCR master solutions.

[0134] The results of the PCR are detected via measuring real-time fluorescence. In particular, as the target copies are being amplified during the PCR reaction, there are more hydrolysis probes (TaqMan probes) that can be hydrolysed, leading to the unquenching of the fluorophore on the hydrolysis probe, which thereupon leads to an increase of the fluorescence signal that is proportional to the initial amount of target copies. Although the results are generally comparable with the results of the conventional method in which the PCR master solution is directly heat-dried in the PCR-chamber, in a number of cases when using tablets the readout of the real-time PCR deviates from the expected outcome. Such a non-uniformity in results would compromise the robustness of a test.

[0135] This difference can be due to a host of factors, which are discussed below.

[0136] Example 2 Extra components in tablets do not affect PCR

[0137] A factor to be considered in ascertaining robustness of a reaction is the presence of extra components, such as stabilisers and fillers, which are used for producing tablets. The extra components are mainly used for increasing the firmness of the tablets. Additionally, the extra components increase the dimensions of the tablets, which facilitates manageability for placing, etc. However, such extra components can influence the PCR step as such. For instance, the components may have an inhibitory effect on the reaction conditions of the PCR.

[0138] The influence of the extra components compared to the heat-dried situation is first tested by performing standard PCRs, i.e. outside the cartridge with and without any of the extra components individually, and comparing the results. Subsequently, a set of PCR experiments is performed in which all extra components as a PCR master solution, as a tablet, and as squashed (crushed) tablets are compared. These three arms of the experiment comprise the same components. Moreover, the time to completely dissolve the tablets as determined in Example 1 is respected. Hence, any -unknown- parameter of the components can thus be ruled out.

[0139] In the same set up, different extra components are tested on possibly influencing the PCR.

[0140] It appears that the extra components as such, e.g. trehalose, which are used to facilitate producing the tablets have a minimal influence on the robustness of the assay, if at all.

[0141] Example 3 Tablets can move in the PCR chamber and impede PCR

[0142] After ruling out the influence of the extra components in the tablets on the PCR in the previous experiments, the only variable appears to be the physical presence of the tablet in the PCR chamber relative to conventional positioning of the PCR components, i.e. heat-drying the PCR components on the bottom layer of the PCR disk.

[0143] It is known that a problem that may be encountered when filling microfluidic devices is the incomplete filling of the portions of the device, such as the PCR chambers. Such incomplete filling may be due to the entrapment of residual volumes of gas (e.g., air), thereby forming one or more bubbles, within one or more portions to be filled. It is desirable to avoid and / or minimize the formation of bubbles within a microfluidic device, as the existence of such bubbles may negatively impact the performance of the device. For example, incomplete filling of portions of the device may negatively impact the reaction efficiency between the sample and, for example, a reagent, and / or the detection of analytes, etc., for which the biological sample is being tested. Moreover, microfluidic devices used for biological testing may rely on optical detection, such as the detection of fluorescence, for example, to determine the presence and / or amount of an analyte of interest. The presence of one or more gas bubbles in the portion of the device at which such optical detection occurs, for example, in a PCR chamber may impair the optical detection. Since the level of fluorescence that can be detected increases with the concentration of the various reaction products in a sample chamber, the presence of one or more gas bubbles in the chamber may effectively decrease the concentration of those products, thus decreasing sensitivity of the optical detection. In addition, optical detection may also be impaired due to the presence of a gas bubble within a PCR chamber by altering the path of light entering and / or exiting the chamber. For example, the path of light may be altered due to a lensing effect created by the curvature of the gas bubble surface and / or due to the gas bubble blocking the light.

[0144] It is anticipated that the form of the dosage forms, e.g. tablets may influence the filling of the PCR chambers with the sample.

[0145] Various forms of the tablets are generated, including round (standard) forms, square forms, parallelograms and elliptical forms. Also a variation in height is introduced, here 0.3 mm, 0.4 mm and 0.5 mm which is less than the standard height of between 0.8-0.9 mm of the tablets from Example 1. The thinner the tablets, the more brittle they become and more difficult to manually manipulate. It is furthermore safeguarded that the different tablets fit adequately in the PCR chambers (cf. Example 1). Moreover, in all cases it is ensured that the same amount of active PCR components is used. If necessary, the amount of extra components is varied, which according to the results of Example 2 would have no influence on the PCR itself.

[0146] In order to actually follow the filling of the PCR chambers with a sample, the PCR disk is not connected with the rest of the cartridge (unpaired, see Example 1), but coupled to a separate pumping and filling device (cf. Example 1 unpaired PCR disk). A highspeed camera device is placed over the PCR disk, which can follow the filling of all 5 PCR chambers simultaneously, and is connected to a computer for recording, magnification and analysis. It appears that the form of the dosage forms (tablets) has only a minor influence on the robustness of the assay. In other words, the variation which is observed with the tablets in the robustness of the assay compared to the standard method does not depend on the form of the tablets. Nonetheless, there is a trend that the variation in results with the thinner tablets is less than with the standard height tablets. This suggests that the liquid of the sample can more easily immerse the thinner tablets and avoid trapping of air bubbles than with the standard height tablets.

[0147] The highspeed camera results show that the tablets can be moved in the PCR chamber and can be pushed forward by the liquid front of the sample filling the PCR chamber. This can result in obstructing the outlet channels, which are used for removing the air bubbles. Thus, the moving tablets can in fact entrap the air bubbles and impede the performance of the assay.

[0148] Example 4 Adaptation of the PCR disk can restore robustness

[0149] After identifying the problem of tablets obstructing the outlet channels of the PCR chambers, the inventor set out to provide a solution, which would preferably be easily implementable and cost effective.

[0150] According to the experiments of Examples 1-3, showing that the tablets as such appear to play no major factor in the performance of the assay, two alternative routes are explored to avoid obstruction of the outlet channels, safeguarding that any adaptation to the PCR chamber may not compromise detection.

[0151] A first route for avoiding air bubble entrapment is adapting the form of the opening of the outlet channel which is in contact with the wall of the PCR chamber. In this case, the height of the outlet channel is extended to the total height of the PCR chamber. Because of this configuration the tablets when shifted cannot obstruct the whole of the outlet channel. This concept is adequate from an assay robustness perspective, but is especially suitable for the thinner tablets, in which the liquid front pushes the air bubble easily over the tablet. However, as mentioned above, this setup requires thinner tablets which are more difficult to manipulate manually. Moreover, this setup also requires a -costly- adaptation to the PCR disk itself.

[0152] A second route for avoiding air bubble entrapment is adapting the form of PCR chamber itself, not just the outlet channel. In this alternative design, the walls of the PCR chamber are slightly oblique from top to bottom. The tablet is positioned on the bottom of the PCR chamber because of the design of the chamber itself. Even if the opening of the outlet channel is located at the bottom of the PCR chamber, the opening cannot be obstructed completely due to its design comprising a retracted upper part. A further preferred design option is to maintain the area and dimensions of the original bottom of the PCR chamber and to only modify, i.e., enlarge, the dimensions of the top area. For instance, the circumference of the top of the cavity is larger than the circumference of the bottom of the cavity. As a result, no adaptations to the detection device or parameters are necessary. Also this concept is adequate from an assay robustness perspective.

[0153] However, all adaptations require adjustments of the manufacturing process of the PCR chambers, including manufacturing new molds.

[0154] Example 5 Clamping the tablet between the top and bottom layer results in a robust assay

[0155] Although the design modifications provided in Example 4 avoid trapping of air bubbles when filling the PCR chamber, and thus guarantee robustness of the assay, it means changing the design of the PCR disk itself. In order to minimally change the hardware design, the present inventor set out to seeking alternative solutions for avoiding trapping air bubbles, while tablets could still be used.

[0156] As discussed in Example 3, minimizing the height of the tablets results in less variation than with the standard height tablets.

[0157] However, the inventor considered an unconventional resolution by instead increasing the height of the tablets to 1.1-1.2 mm which is slightly larger than the height of the wall of the PCR chamber (1.0 mm), in which the position of the tablet would be secured by clamping the tablet between the bottom and the top layer of the PCR chamber (see Figure 2). This design could in principle make use of the conventional PCR disk and -most of the- manufacturing processes.

[0158] Nonetheless, this design has several consequences.

[0159] First, when welding the top foil to the PCR disk the foil must be kept tight, e.g. not loose, otherwise the effect of clamping the tablet is lost. This must be ensured over all PCR chambers of the PCR disk. It turns out that the tension on the top foil when covering the top side of the PCR disk effected by the conventional manufacturing process for welding is sufficient to clamp the tablets in the respective PCR chambers. Hence, for this aspect the conventional manufacturing process does not need to be adapted.

[0160] Second, because of clamping the tablets between the bottom and top foils, there is more tension on the weld seams. The weld seams must be kept intact during storage, transport and processing. For testing the integrity and durability of the weld seams, the conventional manufacturing process as described above is used. The PCR disks are further subjected to the standard quality processes for testing integrity over prolonged periods and during varying conditions, including applying an overpressure and overfilling with liquid and exposure to stress and force. It turns out that the weld seams of the PCR disks with tablets are comparable to the conventional PCR disks.

[0161] Third, because of clamping the tablets between the bottom and top foils, there is more tension on the foils itself. The foils must be kept intact during storage, transport and processing. For testing the integrity and durability of the foils during storage and transport, the conventional manufacturing process as described above is used. The PCR disks are further subjected to the standard quality processes for testing integrity over prolonged periods and during varying conditions (see above). The properties of the foils of the PCR disks with tablets are comparable to the conventional PCR disks, i.e. there are no tears or rips in the foils.

[0162] Fourth, in order to test whether the tablets remain at their original position, i.e. the position when the tablets are clamped between the top and bottom foils, the PCR disks with tablets are also shaken manually. In a further stage, the finished cartridges with the PCR disks of the present invention are subjected to standard quality procedures, including dropping from a 1.8m height.

[0163] From the above, it can be concluded that the conventional manufacturing process is sufficient for clamping the tablets in the PCR chambers.

[0164] As described in Example 3, in order to actually follow the filling of the PCR chambers with a sample, the unpaired PCR disk is coupled to a separate pumping and filling device. A highspeed camera device is placed over the PCR disk, which can follow the filling of all 5 PCR chambers simultaneously, and is connected to a computer for recording, magnification, and analysis.

[0165] Figure 6 shows a schematic representation of the filling process. The tablet remains in its original position during the filling process. The air is pushed out by the liquid front and no remaining air bubbles are detected.

[0166] The above experiments are all performed with a detached (unpaired) PCR disk, i.e. the PCR disk is not operational in a cartridge.

[0167] During transport the PCR disk is retained in the cartridge, and only during nucleic acid amplification the disk is retracted from the cartridge into the PCR / detection apparatus. The total of the bottom foil, tablet and top foil must enable proper functioning of the PCR disk, i.e. the PCR disk must be retracted or pulled out of the cartridge without scratching, tearing or impeding the foil. Obviously, the height dimensions of the PCR disk ensemble must be kept less than the slit in the cartridge, behind which the PCR disk is retained. Preferably, there is also some room for wiggling, in that the height of the slit is substantially larger than the height dimensions of the ensemble, for instance, in case the PCR disk is not pulled out completely straight (horizontally) but with some inclination versus the midline of the cartridge. It is shown that the dimensions of the slit in the conventional cartridge is adequate to handle the PCR disk comprising tablets.

[0168] Next, the concept of tablets clamped between the top and bottom foils is tested under actual nucleic acid amplification and detection conditions. The PCR disk is retracted from the cartridge into the PCR detection device. In order to ensure optimal heat transfer and repeatability the PCR disk can be sandwiched in the PCR detection device. It is hypothesized that the sandwiching and thus crushing the tablets may help dissolving the tablet, if this would not have been effected before. This would reduce the time to dissolve the tablets completely (cf. Example 1).

[0169] During a PCR, the temperature rises at each cycle to over 90°C intended to melt the double stranded nucleic acids, but may also help dissolving the dosage form if not yet completed. Under these conditions, the weld seams also must remain intact even with the produced tension.

[0170] Compared to the conventional method, it appears that in our hands the only variable would be the time for dissolving the tablet compared to dissolving the conventional heat-dried PCR compounds. This will slightly impact the total turnaround time (TAT) from sample to result. If the difference in TAT is deemed of major importance, it is within the person skilled in the art's common knowledge to test suitable excipients facilitating the dissolving process but preferably not affecting the PCR and detection.

[0171] In order to decrease the TAT by facilitating the dissolving process an alternative solution is provided. After manufacturing the PCR disk with tablets, i.e., after welding the top foil to the PCR disk, the tablets can be crushed. This can be implemented at various time points, e.g. after connecting the top foil to the PCR disk, before connecting the completed PCR disk to the rest of the cartridge (see Figure 8), when the PCR disk is inserted into the PCR apparatus, etc. The tablets can be crushed mechanically or manually. In fact, this can be implemented simultaneously with the welding step, although this necessitates an adaptation of the welding device. For the present purposes, some of the tablets were crushed manually while some remained intact. Preferably, the tablets are crushed just before filling the PCR chamber. Except for the time to dissolve, differences are not apparent.

Claims

CLAIMS1. A microfluidic chamber (1) comprising:- a top layer (7) comprising a first material;- a bottom layer (8) comprising a second material, wherein the top layer and the bottom layer oppose each other;- a wall (3) having a first surface (5) and a second surface (6), wherein the first surface of the wall is affixed to the top layer and the second surface of the wall is affixed to the bottom layer, and wherein the top layer, bottom layer, and wall form a cavity (2) of the chamber;- an inlet (12) in the wall;- an outlet (13) in the wall; and- a dosage form, preferably a tablet, (9) that is immobilized in the cavity and that engages the top layer and the bottom layer, wherein engagement with the top layer and the bottom layer immobilizes the dosage form within the cavity, wherein at least one of the first material and the second material is flexible, and wherein at least one of the first material and the second material is transparent.

2. The microfluidic chamber according to claim 1,- wherein the first material and the second material are flexible, and / or- wherein the first material and the second material are transparent, and / or- wherein the dosage form is immobilized in the cavity by the top layer and the bottom layer without an additional physical structure and without chemical action, and / or- wherein the dosage form is not attached to and / or dried onto the top layer or the bottom layer, and / or- wherein the top layer and the bottom layer directly contact the dosage form and hold the dosage form in a defined position within the cavity, and / or- wherein the wall (3) has a first height (18) between the first surface (5) and the second surface (6), and the dosage form has a second height (17) that is greater than the first height, preferably wherein the height ratio of the dosage form to the wall is larger than 1, such as >1.1, >1.2, >1.3 or even >1.4, such as about 1.5, and / or- wherein engagement with the dosage form forces the top layer to protrude above the first surface, and / or- wherein engagement with the dosage form forces the bottom layer to protrude below the second surface, and / or- wherein engagement with the dosage form forces the top layer and the lower layer to deflect away from each other, and / or- wherein the dosage form partially fills the cavity, and / or- wherein the dosage form is positioned in the center of the cavity, and / or- wherein the center point of the dosage form is aligned with the center point of the cavity, and / or- wherein the distance between the dosage form and the inlet is about the distance between the dosage form and the outlet, and / or- wherein the dosage form is not contacting the inlet and / or outlet, and / or- wherein the circumference ratio of the dosage form to the cavity is smaller than 1, such as <0.9, <0.8, <0.7 or even <0.6, such as about 0.5, and / or- wherein the dosage form has circular, ellipsoidal, wiggle, square, diamond, parallelogram shape, preferably, the dosage form is circular, and / or- wherein the dosage form is solid or semi-solid, and / or- wherein the dosage form is a tablet, capsule, bead, or pellet, preferably a tablet, and / or- wherein the dosage form comprises a coating; and / or- wherein the dosage form comprises active ingredients and excipients,• preferably said active ingredients comprise polymerase, deoxyribonucleotide triphosphates (dNTPs), primers and probes,• preferably said excipients comprise stabilisers, disintegrants and optionally fillers, and• preferably said active ingredients and said excipients are evenly distributed throughout the dosage form; and / or- wherein the dosage form has a dissolution rate in which at least 50% of the active substances are dissolved in less than 2 minutes; and / or- wherein the first and / or second material is chosen from polydimethylsiloxane (PDMS) and thermoplastic materials, preferably the first and / or second material is chosen from polyolefin- films (e.g. polyethylene (PE), polypropylene (PP), polybutylene (PB), poly-isobutylene (PIB), ethylene vinyl acetate (EVA) or copolymers of ethylene with acrylate esters), polyester-, polyurethane- and COC-film, or any combination thereof.

3. A microfluidic device comprising at least one microfluidic chamber according to claim 1 or 2, wherein said at least one microfluidic chamber is in fluid connection with a central channel, preferably said device comprises two or more chambers.

4. A method of combining reactants for a nucleic acid amplification reaction in a microfluidic chamber, the method comprising:(1) providing a microfluidic chamber according to any one of claims 1 to 2;(2) adding a sample fluid comprising a nucleic acid into the cavity via the inlet to contact the dosage form; and(3) dissolving the dosage form in the sample fluid to provide a reaction mixture, thereby combining the reactants for the nucleic acid amplification reaction.

5. The method according to claim 4,- wherein, upon adding the sample fluid into the cavity, the dosage form remains immobilized until complete filling of the cavity with the sample fluid; and / or- wherein, upon adding the sample fluid into the cavity, the fluid flows surround the immobilized dosage form until complete filling of the cavity with the sample fluid, preferably the sample fluid generates a first meniscus Ml between the wall and a first side of the dosage form and a second meniscus M2 between the wall and a second side of the dosage form; and / or- wherein, upon adding the sample fluid into the cavity, the amount of air in the cavity upon complete filling of the cavity with the sample fluid is reduced by at least 70%, such as >80%, or even >90%, >95%, or >99%, or even 100%; and / or- wherein adding the fluid comprises flowing the fluid around at least a portion of the dosage form within the cavity; and / or- wherein the dosage form remains immobilized during the step of dissolving the dosage form; and / or- wherein the dosage form is disintegrated before step (3) of dissolving the dosage form.

6. A method of performing a nucleic acid amplification reaction, the method comprising:(1) providing a microfluidic chamber according to any one of claims 1 to 2;(2) adding a sample fluid comprising a nucleic acid into the cavity via the inlet to contact the dosage form;(3) dissolving the dosage form in the sample fluid to form a reaction mixture in the microfluidic chamber;(4) amplifying the nucleic acid in the microfluidic chamber; and(5) detecting the nucleic acid in the microfluidic chamber, thereby performing the nucleic acid amplification reaction.

7. The method of performing a nucleic acid amplification reaction according to claim 6, wherein said microfluidic chamber is wedged between a heat exchanger, such as a PCR device, and detection device after step (2) and before step (3).

8. A reaction element comprising at least one microfluidic chamber (1), said microfluidic chamber (1) comprising:- a top layer (7) comprising a first material;- a bottom layer (8) comprising a second material, wherein the top layer and the bottom layer oppose each other;- a wall (3) having a first surface (5) and a second surface (6), wherein the first surface of the wall is affixed to the top layer and the second surface of the wall is affixed to the bottom layer, and wherein the top layer, bottom layer, and wall form a cavity (2) of the chamber;- an inlet (12) in the wall;- an outlet (13) in the wall; and- optionally a dosage form, preferably a tablet, (9) that is immobilized in the cavity and that engages the top layer and the bottom layer, wherein engagement with the top layer and the bottom layer immobilizes the dosage form within the cavity when present, wherein at least one of the first material and the second material is flexible, wherein at least one of the first material and the second material is transparent, and said reaction element further comprising at least one inlet channel (19, 25) for transporting a sample S to at least one microfluidic chamber (1), wherein said inlet channel comprising at least one valve, and / or said reaction element further comprising at least one outlet channel (20, 25) for expelling air from said one microfluidic chamber (1), wherein said outlet channel comprising at least one valve, and / or and said reaction element further comprising at least one main channel (11, 25) for transporting a sample S to said at least one inlet channel (19), wherein main channel comprising at least one valve.

9. A method for operating a reaction element according to claim 8, wherein said reaction element is wedged between a heat exchanger, such as a PCR device, and a detection device, wherein a valve is closed by said wedging, thereby operating said reaction element.

10. A method of manufacturing a microfluidic chamber comprising: (a) placing a dosage form on top of a first flexible, transparent material that is affixed to a first surface of a wall, the wall comprising an inlet and an outlet;(b) affixing a second flexible, transparent material to a second surface of the wall such that the second flexible, transparent material is over the dosage form and opposes the first flexible, transparent material, wherein the first flexible, transparent material, second flexible, transparent material, and wall form a cavity of the microfluidic chamber, and wherein the dosage form engages the first flexible, transparent material and the second flexible, transparent material and engagement with the first flexible, transparent material and the second flexible, transparent material immobilizes the tablet within the cavity, thereby providing the microfluidic chamber.

Citation Information

Patent Citations

  • Stabilized enzyme compositons for nucleic acid amplification

    EP0726310A1

  • Cartridge, system and method for automated medical diagnostics

    EP1896180A2

  • Cartridge for automated medical diagnostics

    EP1904234A1

  • Treatment of a sample with focused acoustic energy

    EP2419705A1

  • High-throughput nucleic acid polymerase devices and methods for their use

    US20020173016A1